A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).

O. Yellin; J. R. Berenson; T. Kazamel; C. Chen; A. Cartmel; T. B. S. Woliver; M. S. Flam; E. N. Bravin; Y. Nassir; R. A. Vescio; R. Swift; Chien-Shing Chen

doi:10.1200/JCO.2011.29.15_SUPPL.8082

A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).

O. Yellin
, J. R. Berenson
, T. Kazamel
, C. Chen
, A. Cartmel
, T. B. S. Woliver
, M. S. Flam
, E. N. Bravin
, Y. Nassir
, R. A. Vescio
, R. Swift
, Chien-Shing Chen

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	29
DOIs	https://doi.org/10.1200/JCO.2011.29.15_SUPPL.8082
State	Published - May 20 2011

Disciplines

Pharmacology
Medicine and Health Sciences

Access to Document

10.1200/JCO.2011.29.15_SUPPL.8082License: Unspecified

OpenUrl availability

Full text

Cite this

Yellin, O., Berenson, J. R., Kazamel, T., Chen, C., Cartmel, A., Woliver, T. B. S., Flam, M. S., Bravin, E. N., Nassir, Y., Vescio, R. A., Swift, R., & Chen, C.-S. (2011). A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM). Journal of Clinical Oncology, 29. https://doi.org/10.1200/JCO.2011.29.15_SUPPL.8082

Yellin, O, Berenson, JR, Kazamel, T, Chen, C, Cartmel, A, Woliver, TBS, Flam, MS, Bravin, EN, Nassir, Y, Vescio, RA, Swift, R & Chen, C-S 2011, 'A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).', Journal of Clinical Oncology, vol. 29. https://doi.org/10.1200/JCO.2011.29.15_SUPPL.8082

@article{342603ef5a38460ab8a9c30fe9e30b3c,

title = "A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).",

author = "O. Yellin and Berenson, \{J. R.\} and T. Kazamel and C. Chen and A. Cartmel and Woliver, \{T. B. S.\} and Flam, \{M. S.\} and Bravin, \{E. N.\} and Y. Nassir and Vescio, \{R. A.\} and R. Swift and Chien-Shing Chen",

note = "8082 Background: The combination of either pegylated liposomal doxorubicin (PLD) and bortezomib (BORT) or lenalidomide (LEN) and dexamethasone (DEX) have shown significant anti-MM activity. However, both regimens are associated with significant toxicity and produce response rates in only 40-60\% of patients.",

year = "2011",

month = may,

day = "20",

doi = "10.1200/JCO.2011.29.15\_SUPPL.8082",

language = "American English",

volume = "29",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).

AU - Yellin, O.

AU - Berenson, J. R.

AU - Kazamel, T.

AU - Chen, C.

AU - Cartmel, A.

AU - Woliver, T. B. S.

AU - Flam, M. S.

AU - Bravin, E. N.

AU - Nassir, Y.

AU - Vescio, R. A.

AU - Swift, R.

AU - Chen, Chien-Shing

N1 - 8082 Background: The combination of either pegylated liposomal doxorubicin (PLD) and bortezomib (BORT) or lenalidomide (LEN) and dexamethasone (DEX) have shown significant anti-MM activity. However, both regimens are associated with significant toxicity and produce response rates in only 40-60% of patients.

PY - 2011/5/20

Y1 - 2011/5/20

UR - https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.8082

U2 - 10.1200/JCO.2011.29.15_SUPPL.8082

DO - 10.1200/JCO.2011.29.15_SUPPL.8082

M3 - Article

VL - 29

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM).

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this